Update shared on23 Sep 2025
Fair value Increased 9.49%The significant drop in future P/E and improvement in net profit margin point to enhanced profitability expectations for InnoCare Pharma, supporting the upward revision of the consensus analyst price target from HK$15.61 to HK$17.09.
What's in the News
- HIBRUKA (orelabrutinib) approved by Singapore HSA for relapsed or refractory marginal zone lymphoma; previously approved in China for first-line CLL/SLL and multiple other B-cell lymphoma indications, with National Reimbursement Drug List coverage.
- First patient dosed in China registrational trial of BCL2 inhibitor mesutoclax (ICP-248) for BTK inhibitor treated mantle cell lymphoma; mesutoclax in development for four hematologic malignancies globally.
- China NMPA approved IND for clinical trial of B7-H3 targeted ADC ICP-B794 for various solid tumors; no B7-H3 targeted therapies approved globally.
- Board meeting scheduled to consider interim results for six months ended June 30, 2025.
Valuation Changes
Summary of Valuation Changes for InnoCare Pharma
- The Consensus Analyst Price Target has risen from HK$15.61 to HK$17.09.
- The Future P/E for InnoCare Pharma has significantly fallen from 354.11x to 241.48x.
- The Net Profit Margin for InnoCare Pharma has significantly risen from 2.39% to 2.83%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.